D&D Pharmatech Acquires Three Drug Pipeline Rights From Neuraly for USD 3.31 Million
Bitget2026/11/02 02:15- D&D Pharmatech agreed to acquire intellectual property for three drug pipelines from wholly owned U.S. subsidiary Neuraly for USD 3.31 million.
- The transfer, effective Nov. 2, 2026, gives the parent ownership and exclusive development and commercialization rights.
- The pipelines comprise TLY012 for fibrosis, NLY01 for neurodegenerative diseases and NLY12 for metabolic diseases.
- No subsequent royalties are payable between the companies. An independent specialist valued the assets.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
British Pound hits session highs at 1.3420 amid broadbased US Dollar weakness
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Crypto prices
More
